RT Journal Article
SR Electronic
T1 <strong>Imaging </strong><strong>patients with breast and prostate cancers using combined <sup>18</sup>F NaF/<sup>18</sup>F FDG and TOF simultaneous PET/ MRI</strong>
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1455
OP 1455
VO 56
IS supplement 3
A1 Iagaru, Andrei
A1 Minamimoto, Ryogo
A1 Jamali, Mehran
A1 Barkhodari, Amir
A1 Obara, Piotr
A1 Loening, Andreas
A1 Taviani, Valentina
A1 Mittra, Erik
A1 Gambhir, Sanjiv
A1 Vasanawala, Shreyas
YR 2015
UL http://jnm.snmjournals.org/content/56/supplement_3/1455.abstract
AB 1455 Objectives We previously reported the evaluation of a simultaneous PET/MRI scanner with TOF capability, as well as the use of combined 18F NaF/18F FDG PET/CT in cancer patients. Here we compared the combined 18F NaF/18F FDG PET/ MRI against 99mTc-MDP in patients with breast and prostate cancers.Methods 9 patients referred for 99mTc-MDP bone scans were prospectively enrolled from Oct-Dec 2014. The cohort included 6 men with prostate cancer and 3 women with breast cancer, 41 - 85 year-old (average 64 ± 15). 18F NaF (0.7-2.2 mCi, mean: 1.33 mCi) and 18F FDG (3.9-5.2 mCi, mean: 4.6 mCi) were subsequently injected from separate syringes. The PET/MRI was done 6-12 days (average 9.3 ± 3.2) after bone scan. The whole body MRI protocol consisted of T2-weighted, SSFSE, DWI, and contrast-enhanced T1-weighted imaging. Lesions detected with each test were tabulated and the results were compared.Results All patients tolerated the PET/MRI exam, and PET image quality was diagnostic despite the marked reduction in the administered dosage of radiopharmaceuticals (80% less for 18F NaF and 67% less for 18F FDG). Two patients had no bone metastases identified on either scans. Bone scintigraphy and PET/MRI showed osseous metastases in 7 patients, but more numerous bone findings were noted on PET/MRI than on bone scintigraphy in 3 patients. Lesions outside the skeleton were identified by PET/MRI in 2 patients.Conclusions The combined 18F NaF/18F FDG PET/MRI is superior to 99mTc-MDP scintigraphy for evaluation of skeletal disease extent. Further, it detected extra-skeletal disease that may change the management of these patients, while allowing a significant reduction in radiation exposure from lower dosages of PET radiopharmaceuticals administered. A combination of 18F NaF/18F FDG PET/MRI may provide the most accurate staging of patients with breast and prostate cancers prior to the start of treatment.Research Support GE Healthcare